Loading...
01/11 11:08
Loading...
Silence Therapeutics PLC (SLN) is set to release its earnings performance on 11/06 05:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 5.63M and an earnings per share (EPS) of -0.40 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings call highlights financial challenges, such as a net operating loss and dependency on securing a partner for Phase 3 studies, which could delay progress. Despite increased revenue, the company's financial health remains precarious with significant R&D expenses. The Q&A section reveals management's reluctance to provide clarity on partnerships, raising concerns about execution risks. These factors, combined with competitive market pressures and supply chain challenges, suggest a negative sentiment towards the stock's short-term performance.
The earnings call reveals moderate revenue growth and improved net loss, but lacks strong catalysts like new partnerships or guidance upgrades. Management's vague responses in the Q&A and uncertainties around partnerships and competition present potential risks. The decision to delay the Phase 3 trial until a partner is secured extends the cash runway, but doesn't provide immediate positive impact. Overall, the mixed signals and lack of decisive positive news suggest a neutral sentiment for the stock price over the next two weeks.
The earnings call revealed mixed signals. The company reported strong revenue growth and secured significant milestone payments, indicating positive financial performance. However, rising R&D costs and net losses are concerning. The Q&A section highlighted operational challenges and competitive pressures but also showed promising clinical data and potential partnerships. Overall, the sentiment is neutral due to the balance of positive revenue growth and financial challenges, along with the cautious tone in the Q&A section.
Silence Therapeutics PLC (SLN) is scheduled to release its FY2025Q3 earnings report onNov 6, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 5.63M in revenue and an EPS of -0.40 for Silence Therapeutics PLC's FY2025Q3.
Intellectia's exclusive AI algorithms forecast a forSilence Therapeutics PLC's FY2025Q3 earnings, with a prediction date of Nov 6, 2025. Silence Therapeutics PLC
Leverage Intellectia's AI forecast to position trades ahead of theNov 6, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
